On August 17, 2022, HTG Molecular Diagnostics, Inc. convened and adjourned 2022 Annual Meeting of Stockholders, without any business being conducted, due to a lack of quorum. The 2022 Annual Meeting was adjourned until 1:00 p.m. Pacific Time on September 15, 2022. James T. LaFrance's term of office was scheduled to expire at the 2022 Annual Meeting.

In addition, as previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2022, Harry A. George notified the company on June 23, 2022 of his decision to resign from Board of Directors on the date of the 2022 Annual Meeting. In light of the adjournment of the 2022 Annual Meeting until September 15, 2022, on August 17, 2022, each of Mr. LaFrance and Mr. George resigned from the Board, effective on August 18, 2022. On August 18, 2022, the Board appointed Thomas W. Dubensky Jr., Ph.D. to the Board, effective concurrently with the resignation of Mr. LaFrance, to serve as a Class I director with a term of office expiring at the annual meeting.

Dr. Dubensky was also appointed to serve as a member of the Compensation Committee of the Board. Dr. Dubensky is named in the Notice and proxy materials for the annual meeting as a nominee for election at the meeting. The Board also appointed Lee R. McCracken to serve as a member of the Audit Committee of the Board.